Fortress Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Fortress Biotech, Inc. (FBIO) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $368.34 thousand as of 2021-12-31, per its 10-K filed 2022-03-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2022-03-28
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $368.34K.
- 2021-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $666.96K.
- 2020-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $603.37K.
- 2020-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $214.74K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2021-12-31 | $368.34K 10-K · filed 2022-03-28 |
| 2021-09-30 | $666.96K 10-Q · filed 2021-11-15 |
| 2020-06-30 | $603.37K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $214.74K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $545.75K 10-K · filed 2020-03-16 |
| 2019-09-30 | $15.15M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $49.25M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $155.32M 10-Q · filed 2019-05-10 |
| 2018-09-30 | $87.13K 10-Q · filed 2018-11-09 |
| 2018-06-30 | $719.32M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $1.70B 10-Q · filed 2018-05-10 |
| 2017-12-31 | $1.35B 10-K · filed 2018-03-16 |
| 2017-09-30 | $1.62B 10-Q · filed 2017-11-09 |
| 2017-06-30 | $1.83M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $1.22B 10-Q · filed 2017-05-10 |
| 2016-12-31 | $602.45M 10-K · filed 2017-03-16 |
| 2016-09-30 | $710.27K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $573.66K 10-Q · filed 2016-08-09 |
| 2016-03-31 | $805.65K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $633.05M 10-K · filed 2016-03-15 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-10 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-16 |
| 2013-12-31 | $0.00 10-K · filed 2014-03-14 |
| 2013-09-30 | $4.27M 10-Q · filed 2013-11-01 |
| 2013-06-30 | $6.03M 10-Q · filed 2013-08-05 |
| 2013-03-31 | $5.98M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $2.19M 10-K · filed 2013-03-18 |
| 2012-09-30 | $1.87M 10-Q · filed 2012-11-14 |
| 2012-06-30 | $1.52M 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |